Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07ZZD
|
||||
Former ID |
DNC014181
|
||||
Drug Name |
4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [530609] | ||
Structure |
Download2D MOL |
||||
Formula |
C14H17N3O
|
||||
Canonical SMILES |
C1CN2CCC1N(CC2)C3=NC4=CC=CC=C4O3
|
||||
InChI |
1S/C14H17N3O/c1-2-4-13-12(3-1)15-14(18-13)17-10-9-16-7-5-11(17)6-8-16/h1-4,11H,5-10H2
|
||||
InChIKey |
CXJLWJAYGMWLRR-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine receptor 3A | Target Info | Inhibitor | [530609] | |
KEGG Pathway | Serotonergic synapse | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | 5HT3 type receptor mediated signaling pathway | ||||
Reactome | Ligand-gated ion channel transport | ||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Iron uptake and transport | |||||
References | |||||
Ref 530609 | J Med Chem. 2010 Feb 11;53(3):1222-37.Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. | ||||
Ref 530609 | J Med Chem. 2010 Feb 11;53(3):1222-37.Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.